This needs to be investigated as possible abuse of power
AI company Anthropic has paid $1.63 million to two lobbying firms tied to Secretary of State Marco Rubio and former White House chief of staff Susie Wiles.
Since April 2025, Anthropic has paid $740,000 to Continental Strategy, whose DC office is run by Rubio's former Senate chief of staff, Alberto Martinez, and where Wiles' daughter Katie works. On March 9, 2026, it hired Wiles' former firm, Ballard Partners, for $890,000.
Ballard's team on the account includes former Rubio State Department adviser Micah Ketchel and former deputy DNI Amaryllis Fox Kennedy, RFK Jr.'s daughter-in-law.
Weeks later, Rubio's March 30 memo set off the fall of Nvidia CEO Jensen Huang, a longtime opponent of Anthropic's push to restrict chip sales to China. Huang was then turned away from meetings with Rubio three times.
Continental went on to lobby Rubio's National Security Council and State Department for Anthropic.
Follow: @AFpost
😮
Anthropic Paid Rubio's Ex-Chief Of Staff's Firm $740,000. After The Jensen Memo, It Lobbied His NSC zerohedge.com/political/anth…
1
327
Had to save the stock
Over the past week, I’ve been overwhelmed by the love and support of friends, industry colleagues, and people I've never met. Thank you to everyone who has shown kindness to my family and me. It means the world to me.
I came to the United States 53 years ago, and becoming an American citizen is one of the greatest gifts and proudest moments of my life. NVIDIA has been my life’s work. Building it into the company it is today alongside my colleagues has been a privilege and an honor. Nowhere but in America could a company like NVIDIA be possible. I love our country, and I love NVIDIA.
I did not live up to the standards expected of everyone at NVIDIA, and I have made serious mistakes in my personal life. I created problems for the Board that I deeply regret. I own my mistakes completely, and I am committed to cooperating with the Board’s independent investigation.
Since my departure, I’ve seen an outpouring of calls from NVIDIA’s employees, investors, business partners, and customers for me to return as CEO. Many continue to reach out to me directly as the company navigates complex technology, market, competitive, and geopolitical dynamics. NVIDIA is a once-in-a-generation company. If the Board of Directors decides that my return is in the best interest of our shareholders, our employees, the company, and America, I would be honored to answer these calls and return as CEO.
Thank you again to everyone who has shared their good wishes. I am profoundly humbled by your support. To my family: I love you, and I will spend the rest of my life being worthy of yours.
Jensen
4
450
💯
$NVDA I hope that Anthropic IPO tanks. They played dirty. Jensen was a huge advocate for open AI models which allow smaller companies to compete with giants like Anthropic that control proprietary AI. There are billions of dollars at stake.
I suspect powerful political and corporate interests wanted him out because he was challenging that control.
1
4
623
Do site networks really have twice the patient completion rate of independent sites? I looked at the numbers, the comparisons, and who has a stake in the answer.
1
2
712
Dan Sfera retweeted
$IOVA | JEFFERIES CONFERENCE RECAP: PRICING POWER AND THE PHASE 3 CATALYST
The Jefferies Global Healthcare Conference in London just wrapped up. The management team (CFO, CCO, CMO, and Interim CEO) delivered a masterclass in execution. No new magic tricks, just solid fundamentals. Here are the two most important takeaways that the market is undervaluing.
1. PRICING POWER = CASH FLOW ACCELERATION
CCO Dan Kirby dropped a massive detail: Starting January 1, Iovance is implementing a 9% price increase on Amtagvi and a 7% increase on Proleukin.
Why does this matter? It's pure operating leverage. With a gross margin already at 60%, this price hike goes straight to the bottom line. It means more cash flow, faster profitability, and a stronger balance sheet. When a company has the confidence to raise prices in a competitive market, it tells you everything about the demand for their product.
2. THE REAL CATALYST: TILVANCE-301 (Frontline Melanoma)
While the market is obsessed with the NSCLC noise, the CEO confirmed that the Phase 3 TILVANCE-301 trial (Amtagvi + Keytruda in frontline melanoma) is "definitely on track" and meets (or exceeds) FDA requirements.
The data from the COM-202 cohort (frontline) showed a response rate over 60% with an unprecedented Complete Response (CR) rate. The manuscript is being prepared for publication. If TILVANCE-301 succeeds, the melanoma market triples (from 8,500 to over 22,000 patients in the US alone). This is the catalyst that will force a violent re-rating, and it is moving forward exactly as planned.
THE REST OF THE PICTURE:
- Cash: $382M, runway into 2029. No ATM left, no dilution risk.
- International: UK and Switzerland approvals expected in Q1 2027.
- Manufacturing: The Philadelphia facility is modular and can handle all future demand without building new plants.
THE BOTTOM LINE
The commercial engine is scaling (price hikes), and the pipeline is advancing (TILVANCE-301). The market is distracted by the legal noise and the NSCLC data, but the real value of Iovance is being built right now.
We don't trade headlines. We audit the execution.
Disclaimer: This is not financial advice. I am a shareholder sharing personal research based on public SEC filings and the Jefferies conference transcript.
Dan Sfera retweeted
$AQST - The Jefferies conference was basically a redo of the Q3 earnings call. There were 2 questions at the end that CEO Dan Barber handled nicely. One question was whether Anaphylm PD profile an “overkill” due to the high epinephrine concentration and high blood pressure unpleasant to physicians. Dan’s answer was it’s better for the patients to reduce their symptoms as quickly as possible so they may not need a second dose rather than the patient not getting enough on the first dose. Doctors know this by the way.
The second question was in diastolic blood pressure increase seen more with Anaphylm than others. The answer was it’s just the film technology and the patient getting epinephrine directly to the blood stream may cause that BUT THE FDA PUT IT WRITING THAT THEY HAVE NO CONCERNS ABOUT THE CARDIOVASCULAR IMPACT OF ANAPHYLM.
ir.iovance.com/events/event-…
Dan Sfera retweeted
$IOVA - This was a really good conference for management to restate their strategy to investors. Here are some key points:
1. There is no difference in efficacy with the low dose of lymphodepletion in the LUN-202 data. Shorts were trying to push this fake news. I have said that the lower dose was used early on in the trial after it was briefly halted. THE MAJORITY OF THE DATA IS THE LOWER DOSE AND AS YOU HAVE SEEN THE DATA IS VERY CONSISTENT FROM THE PREVIOUS DATA CUT. So no difference!
2. Management feels mDOR may not be reached by the time they have data on the rest of the 11 patients AS THEY HAVE SAID ALL THIS TIME. They see a similar trend in mDOR with second line melanoma trial.
3. They feel really good about the current data and will file for broad indication in second line mNSCLC. It’s way better than what patients have in this setting. The unmet need is massive. They stress that other current treatments expose patients to repetitive toxicity where as Amtagvi is a 1 time treatment with durable efficacy. This is what will get Amtagvi approved.
4. They will file for the subtype population of KRAS wild-type HER2 wild-type current or ever smoker separately after the sBLA for broad population.
5. Annual maintenance will happen every year but it will no longer interfere with manufacturing.
6. Corleen feels VERY GOOD ABOUT MEETING THE GUIDANCE $410-420. I think they will beat the $420.
7. Margins will continue to improve but may not go in a straight line. Corleen feels confident about margins improving.
8. Management is very excited about soft tissue sarcomas and enrollment is going very well. 55.6% ORR is 10x better than standard of care of 5% or less. The TAM is the same as second line melanoma
9. ATCs will be at 110 or higher by end of year
10. Management expects sales growth will continue
11. Amtagvi price will increase by 9% and Proleukin by 7% starting January 1, 2027
The conference just reiterated what I believe all along. Amtagvi will be approved for NSCLC. Amtagvi alone would make the market cap at $10B at least for second line melanoma in a couple of years. By then, frontline should be approved as well. After that it’s soft tissue sarcomas. Then IOV-5001 with several types of solid tumors. The future is very exciting for @IovanceBio
ir.iovance.com/events/event-…
If true then damn
$NVDA was stuffing every GPU it could into startups on 12 month payment plans, knowing they couldn’t afford it. Jensen was fired because all of the fake “insatiable demand story” broke in Q2 when Nvidia AR jumped 55% in a single quarter because they couldn’t handle the oversupply anymore.
Recognized every dollar of revenue and income while not receiving a penny on it. Thats why Jensen was fired. Cooking the books.
3
4
890
Chinese data doesn’t carry well
FDA rejects Summit Therapeutics’ ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class fiercepharma.com/pharma/fda-…
Bpc-157
Luka Dončić woke up with no pain in his ankle on Thursday and is feeling good, per @ShamsCharania 🔥
Luka injured his ankle on a step-back but is expected to play in the Lakers’ next game 💪
2
516
Dan Sfera retweeted
$AQST - Will be in double digits.
I had lunch with on Tuesday with a manager of a large medical clinic. She said she gets severe hives when she accidentally eats shellfish. I asked if she was prescribed a rescue epinephrine and she said yes but the EpiPen is at home. She said they’re too bulky to carry with her. I said there’s another epinephrine on the market that’s a nasal spray called Neffy. She didn’t know. I said no injections. She said nice! I will look into getting that. I said but you still have to remember to carry the two nasal sprays with you. It’s less bulky than EpiPen.
Then I said or you can wait for another option. It’s called Anaphylm. It’s waiting to be approved by the FDA. It’s a film that you put under your tongue. You don’t even have to swallow. Epinephrine is absorbed by sublingual tissue (under the tongue) rather than being swallowed into the digestive tract. It works faster than other options on the market right now. Best of all, it can be carried on the back of your phone.
She said, “Really?! That’s awesome! I will wait for that one!”
I have had similar conversations with doctors, PAs, NPs, and I get the same in awe responses when it comes to which option they would prescribe for their patients. Two years ago I said SPRY is in a tough situation. They have worked so hard to get a Neffy approved only to see Anaphylm coming to the market soon after. I am telling you right now, Anaphylm will put ARS out of business. Anaphylm is too good. Aquestive conducted a survey among patients, healthcare providers and caregivers. They overwhelmingly chose Anaphylm. It’s not even close.
Don’t take my word for it. Ask yourself the same question. Based on the convenient features and the efficacy of Anaphylm, would you even think about another option if it’s for yourself or someone you care about?
The choice is Anaphylm, and it’s an easy one.
Dan Sfera retweeted
$AQST - Richard Daly - Board of Director member bought shares on open market. 💥



























